RxDoctor Payments Data

Harini Hosain, MD

Allergy & Immunology · Bloomfield, CTNPI 1801819255

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by GSK at 24.7% of the total. 2025 is the largest year on record at $261, 5.6 times the $47 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in CT, where the typical reported total is $2,044.

$445in general payments, 2019–2025

Across 21 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$110
  • CSL Behring$68
  • Takeda Pharmaceuticals U.S.A., Inc.$66
  • Regeneron Healthcare Solutions, Inc.$51
  • Novartis$46
  • ARS Pharmaceuticals Operations, Inc.$30
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$445 in reported general payments places this provider in the 30th percentile of 54 allergy & immunology providers in Connecticut.

See all allergy & immunology providers in Connecticut

Medicare billing

Part B allowed, 2024
$41,113
Medicare patients
68
Services billed
1,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol16$12,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,968
Arnuity ElliptaFluticasone Furoate25$7,405
Qvar RedihalerBeclomethasone Dipropionate21$6,050
Azelastine Hcl117$5,795
SymbicortBudesonide/Formoterol Fumarate16$5,641
Epinephrine27$3,609
Zafirlukast17$1,931
Olopatadine Hcl19$1,708
Montelukast Sodium156$1,597
Wixela InhubFluticasone Propion/Salmeterol21$1,228
Albuterol Sulfate HfaAlbuterol Sulfate58$897
Fluticasone Propionate17$728
Ipratropium Bromide11$510
Desloratadine19$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$110$28,42353 claims
AstraZenecaSymbicort$23$5,64116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 54 allergy & immunology providers in Connecticut.

Other allergy & immunology in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →